Duke spin-out Aerie Pharmaceuticals sets its pre-IPO price range.

Aerie Pharmaceuticals has set its pre-initial public offering (IPO) price range following the announcement of its intention to float on the Nasdaq as reported in GUV last month. The Duke University spin-out will be pricing shares between $12-$14 each, has registered 6 million shares, and has a maximum offering price of $85m. The US-based firm,…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.